Cover Image: October 2011 Scientific American Magazine See Inside

A New Ally against Cancer: Vaccines [Preview]

The FDA recently okayed the first therapeutic cancer vaccine, and other drugs that enlist the immune system against tumors are under study















Share on Tumblr



Image: Photograph by Dan Saelinger

In Brief

  • Conventional treatments for cancer—surgery, chemotherapy and radiation—have increased survival rates since the 1970s, but many survivors still do not achieve a normal life span.
  • Researchers believe the results would be better if they could recruit a new ally against malignancy: the body’s own immune system.
  • Over the past decade several attempts to boost the immune response artificially—through vaccination or other drug development—have failed.
  • But the tide seems to be changing. A cancer vaccine for treating prostate cancer has been approved, and a new generation of therapeutic cancer vaccines is now being tested.

For decades cancer specialists have offered ­patients three main therapies: surgery, chemotherapy and radiation. (Some cancer survivors pointedly refer to this harsh trinity as “slash, poison and burn.”) Over the years continual refinements in these admittedly blunt instruments have made the more severe side effects increasingly manageable. At the same time, effectiveness has improved markedly. And new, very targeted drugs (Herceptin and Gleevec) have become available for a few specific cancers. All told, the average five-year survival rate for invasive cancers as a group has risen from 50 percent to 66 percent in the past 30-plus years. In spite of these gains, many cancer survivors will not have a normal life span.

Researchers have long suspected that they could add a weapon that would dramatically increase cancer survival rates without producing serious side effects if they could just figure out how to prod the body’s own immune system to do a better job of fighting malignancies. But decades of effort met with one failure after another. In the 1980s, for instance, overheated hopes that an immune system molecule called interferon would rouse the body’s defenses to cure all or most cancers were dashed after a few more years of research. Today interferon has a place but is not the cure-all once envisioned. By the first decade of this century a great number of clinical trials were being conducted using lots of different types of vaccine-related approaches, but nothing seemed to be working. It was starting to look as though the long-hoped-for general weapon against a broad range of tumors would never materialize.


This article was originally published with the title A New Ally against Cancer.



Subscribe     Buy This Issue

Already a Digital subscriber? Sign-in Now
If your institution has site license access, enter here.

2 Comments

Add Comment
View
  1. 1. lamorpa 11:11 AM 10/12/11

    I am legend...

    Reply | Report Abuse | Link to this
  2. 2. Xiaohei 09:54 AM 10/22/11

    I THINK SOME CANCER WILL BE PREVENTED BY EFFECTIVE VACCINE IN FUTURE.

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

More »

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital

Latest from SA Blog Network

  SA Digital

Science Jobs of the Week

Email this Article

A New Ally against Cancer: Vaccines: Scientific American Magazine

X
Scientific American Magazine

Subscribe Today

Save 66% off the cover price and get a free gift!

Learn More >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X